IDXG · Interpace Biosciences, Inc.
Market Cap
$42.19M
Shares
5.54M
Volume · Feb 25
186.4K
Avg daily vol (3M)
—
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.25
Open$3.63
Day$3.15–3.80
52W close$2.84–9.08
Avg vol 30d275K
Short int94 · 0.0% float · 1.0d
Short vol1%
Last earningsJan 20, 2021
DataJan 2020–Feb 2021
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$36.14M
Trailing 12 months
Net income (TTM)
$24.45M
Trailing 12 months
Revenue growth YoY
-1.1%
Year over year
Operating margin
11.5%
Trailing 12 months
P / E (TTM)
0.6
Trailing earnings · reciprocal yield 155.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+526.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−21%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
7%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−22%
trailing
6-month return
+6%
trailing
YTD return
+4%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-77% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +3.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
3 holders — near 1-yr low, contrarian setup
Fundamentals
Revenue growth
−31%
Y/Y
Gross margin
425%
expanding
EPS growth
+123%
Y/Y
Free cash flow
$5.5M
Balance sheet
$2.4M
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
17.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Thyroid revenue growth
· remainder of 2026
16%
Prior guidance
period ended
· from the 8-K filed Oct 15, 2026
Preliminary, unaudited revenue
· third quarter ended September 30, 2026
$10.1M – $10.4M
Guided vs delivered
· last 1 settled
Full-year 2023 revenue
full-year 2023
guided at least $40M
$40.04M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-77% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +3.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
3 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3
Now $3 · 7%
Range high $9
vs 200-day avg -23%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.3M | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 8% | Q2 2026 | — |
| Average thyroid revenue per test year-over-year increase | 3% | Q2 2026 | — |
| Average volume per account year-over-year increase | 4% | Q2 2026 | — |
| Cash collections | $8.8M | Q2 2026 | — |
| Days sales outstanding (DSO) improvement | 3% | Q2 2026 | — |
| Number of accounts year-over-year increase | 5% | Q2 2026 | — |
| Thyroid revenue year-over-year increase | 9% | Q2 2026 | — |
| Thyroid volume year-over-year increase | 6% | Q2 2026 | — |
| Trailing twelve-month thyroid revenue | $36.1M | Trailing twelve months ended June 30, 2026 | — |
| Trailing twelve-month thyroid test volume growth | 10% | Trailing twelve months ended June 30, 2026 | — |
| Turnaround time improvement | 17% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IDXG
this stock
Interpace Biosciences, Inc.
|
$42.19M | — | -30.7% | — | 0.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$251.20B | +18.6% | +14.5% | 36.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.77B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.57B | +77.2% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +27.1% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
3
- % held
- 0.0%
- Net QoQ
- -51.8K sh
- Top holder
- HRT FINANCIAL LP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IDXG | -20.0% | -22.1% | +5.9% | -19.2% | +3.5% |
| SPY | -2.2% | +2.1% | +6.9% | +3.3% | +2.3% |
| vs SPY | -17.8% | -24.2% | -1.0% | -22.5% | +1.2% |